LAK (lymphokine acitivated killer) cells, generated by incubation of lymphocytes with interleukin 2 (IL2), have cytotoxicity against fresh tumor cells, and adoptive immunotherapy of cancer with LAK is on clinical trial. OMAK (oxydizing mitogen activated killer) cells are generated by incubation of oxydizing mitogen treated lymphocytes with IL2. This study was designed to compare the cytotoxicities and the proliferation responses of LAK and OMAK at various human AB serum (HABS) concentrations and durations of culture.
Peripheral blood mononuclear cells, treated (OMAK) or untreated (LAK) with periodate, were incubated in RPMI1640 with 10% IL2 and various concentrations of HABS. Proliferation responses were measured by ³H-thmidine uptake and cytotoxicites against K562 and RC29 (NK resistant) were measured by 4-hour ^(51)Cr release method.
OMAK showed higher prolfieration response and cytotoxicity against K562 and RC29 than LAK at 2nd day of culture with 5% HABS. Proliferation responses of LAK and OMAK increased in HABS added culture but cytotoxicitiesdid not. Rather, cytotoxicities were hinger in LAK and OMAK cultured without HABS.
Proliferation responses were not apparent at 1st day of culture. Peak responses were at 7th day in LAK and at 4th day in OMAK. Cytotoxicities against K562 were apparent at 1st day of culture in LAK and OMAK, and peaked at 4th day in LAK and at 3rd day in OMAK, but increment of cytotoxicities were only slight. Cytotoxicities against RC29 appeared at 2nd day in LAK and at 1st day in OMAK. LAK showed peak cytotoxicity from 3rd day to 7th day, but OMAK showed peak cytotoxicity at 3rd day and decreased afterwards.
OMAK may have more advantages than LAK because of its higher and earlier-generated cytotoxicity.
|